- Home
- SILC vs FATE Comparison
SILC vs FATE Comparison
Compare SILC & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- FATE
- Stock Information
- Founded
- SILC 1987
- FATE 2007
- Country
- SILC Israel
- FATE United States
- Employees
- SILC N/A
- FATE N/A
- Industry
- SILC Computer Manufacturing
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SILC Technology
- FATE Health Care
- Exchange
- SILC Nasdaq
- FATE Nasdaq
- Market Cap
- SILC 99.6M
- FATE 116.5M
- IPO Year
- SILC 1994
- FATE 2013
- Fundamental
- Price
- SILC $18.59
- FATE $1.34
- Analyst Decision
- SILC Hold
- FATE Hold
- Analyst Count
- SILC 1
- FATE 6
- Target Price
- SILC N/A
- FATE $3.70
- AVG Volume (30 Days)
- SILC 23.4K
- FATE 3.0M
- Earning Date
- SILC 10-30-2025
- FATE 11-12-2025
- Dividend Yield
- SILC N/A
- FATE N/A
- EPS Growth
- SILC N/A
- FATE N/A
- EPS
- SILC N/A
- FATE N/A
- Revenue
- SILC $58,651,000.00
- FATE $8,470,000.00
- Revenue This Year
- SILC $6.53
- FATE N/A
- Revenue Next Year
- SILC $14.10
- FATE N/A
- P/E Ratio
- SILC N/A
- FATE N/A
- Revenue Growth
- SILC N/A
- FATE N/A
- 52 Week Low
- SILC $12.29
- FATE $0.66
- 52 Week High
- SILC $19.37
- FATE $3.50
- Technical
- Relative Strength Index (RSI)
- SILC 63.52
- FATE 47.45
- Support Level
- SILC $16.75
- FATE $1.42
- Resistance Level
- SILC $17.50
- FATE $1.94
- Average True Range (ATR)
- SILC 0.64
- FATE 0.17
- MACD
- SILC 0.07
- FATE -0.02
- Stochastic Oscillator
- SILC 95.96
- FATE 6.25
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.